InvestSMART

Orthocell Limited (ASX:OCC)

ALERT: Price-sensitive ASX Announcement for OCC
Current share price for OCC : $0.850 0.07 (8.97%)+
Announcement
Release
18 Mar 2026 9:57AM
Price at Release
$0.780
Full Release
download
Summary
Orthocell Limited announced that its Remplir™ nerve repair device was successfully utilized in 23 surgical procedures on injured Ukrainian soldiers. The device, which is designed to connect and protect severed nerves resulting from trauma, was used following remote training provided by Orthocell's Key Opinion Leader, Dr. Alex O'Beirne. The company received positive feedback from Ukrainian surgeons regarding the device's ease of use and portability, highlighting its suitability for major trauma applications. Orthocell is considering further opportunities to support engagement with global defence organizations and intends to continue collaboration with Ukrainian surgeons to monitor outcomes and gather clinical data.
Key Points
  • Remplir™ Nerve Repair was used in 23 surgeries on Ukrainian soldiers.
  • Orthocell Limited provided remote training for Ukrainian surgeons.
  • Remplir™ is designed to connect and protect severed nerves.
  • Orthocell is exploring further engagement with global defence organisations.
  • The device is noted for its portability and ease of use in trauma situations.
  • Orthocell's Managing Director emphasized the importance of Remplir™ in trauma-related nerve injuries.
  • The company received positive feedback from Ukrainian medical professionals.
  • The device has a three-year shelf life and is easily transportable.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.